Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Medacta : Announces Successful Completion of the First Australian Surgery with NextAR TKA Augmented Reality-Based Surgical Platform following TGA Approval

09/04/2020 | 01:00pm EST


EQS Group-Media / 04.09.2020 / 19:00

Media Release

Medacta Announces Successful Completion of the First Australian Surgery with NextARTM TKA Augmented Reality-Based Surgical Platform following TGA Approval

CASTEL SAN PIETRO, 04 September 2020 - Medacta announced today successful completion of the first surgery utilizing its NextARTM TKA, following recent approval from Australia's Therapeutic Goods Administration (TGA).

The surgery was performed by Dr Michael McAuliffe (MBBS FRACS) at St Andrew's Ipswich Private Hospital in Queensland, Australia. Dr McAuliffe is a member of the expert surgeon panel that Medacta collaborated with to develop the NextARTM TKA Application.

Following the surgery, Dr McAuliffe stated that "the NextAR Surgical System offers a rapid, intuitive and user-friendly assessment of the patient's bony anatomy, and most importantly, the soft tissues of the knee joint. Understanding both these facets allows for better personalization of the knee surgery and is likely to significantly improve patient outcomes."

NextARTM is a very competitive solution which is perfectly in line with Medacta's strategic pillar of healthcare sustainability. Designed with the goal to improve efficiency and precision in total knee replacement and support personalized surgery, the NextARTM TKA is an augmented reality-based surgical platform for total knee replacement. This innovative platform, involving augmented reality glasses and a revolutionary infrared single-use tracking system, requires low upfront capital investment by clinics and hospitals, with significant economic benefits to the healthcare system. Dr McAuliffe also commented that "the NextAR Augmented Reality Smart glasses provided a practical benefit to the surgical workflow, allowing visualization of all the necessary information in real-time."

Claire Thurwood, CEO of St Andrew's Ipswich Private Hospital, said: "St Andrew's Ipswich Private Hospital is delighted to broaden its suite of surgical options for patients requiring total knee replacements, with the addition of this new platform. We are incredibly invested in ensuring that our patients and surgeons have access to state-of-the-art technology, with the aim of improving patient outcomes. St Andrew's Ipswich has grown significantly in size over the past two years, and embracing new technology will play a large role in our future moving forward."

By collaborating with expert surgeons from all over the world, Medacta is able to develop innovative products and solutions in-house with minimal lead-time. Dr McAuliffe used the NextARTM TKA in conjunction with the Medacta GMK Sphere Medially Stabilized Knee implant. This innovative total knee implant is designed to deliver maximum functional stability and to facilitate restoration of natural patient-specific kinematics.

Francesco Siccardi, CEO of Medacta, said "I am very proud of this successful first surgery with our new NextAR TKA. I'd like to thank all the NextAR Development Team, surgeons and engineers that made this vision become a fantastic product in such a short period of time. The feedback we are receiving is very positive and I am confident that it will be a game-changer in the years to come. We look forward to extending this technology to spine, shoulder, and hip procedures, with the goal of improving the experience of orthopaedic surgeons and their patients with a very competitive and sustainable healthcare solution."

For more information on the NextARTM Platform, please visit nextar.medacta.com

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated MySolutions technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



Issuer: Medacta Group SA
Key word(s): Research/Technology

End of Corporate News


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch,investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1127853

 
End of News EQS Group Media

1127853  04.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1127853&application_name=news&site_id=zonebourse_sftp

© EQS 2020
All news about MEDACTA GROUP SA
11/04MEDACTA : proposes the election of Riccardo Braglia as new independent member of..
EQ
10/19MEDACTA : Expands its Knee Offerings with New SensiTiN System with Low Metal Ion..
EQ
10/13MEDACTA : Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spin..
EQ
09/29MEDACTA : Expands its Knee Portfolio with 3DMetal Femoral Cones for Knee Revisio..
EQ
09/15MEDACTA : Expands its Partial Knee Replacement Solutions with MOTO Lateral Parti..
EQ
09/07MEDACTA : Publication of 2020 Half Year Results
EQ
09/04MEDACTA : Announces Successful Completion of the First Australian Surgery with N..
EQ
09/02MEDACTA : Receives FDA Clearance for the Lateralized Glenosphere
EQ
07/22MEDACTA : Half-year 2020 revenue equal to Euro 135M, down 11.1% over the prior y..
EQ
07/13MEDACTA TO INTRODUCE NEXTAR(TM) : First FDA-Cleared Augmented Reality-Based Surg..
EQ
More news
Financials
Sales 2020 303 M 362 M 362 M
Net income 2020 31,2 M 37,3 M 37,3 M
Net Debt 2020 114 M 136 M 136 M
P/E ratio 2020 50,6x
Yield 2020 0,53%
Capitalization 1 573 M 1 882 M 1 882 M
EV / Sales 2020 5,57x
EV / Sales 2021 4,61x
Nbr of Employees 1 126
Free-Float 30,7%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 77,35 €
Last Close Price 78,64 €
Spread / Highest target 16,3%
Spread / Average Target -1,64%
Spread / Lowest Target -25,9%
EPS Revisions
Managers
NameTitle
Francesco Siccardi Chief Executive Officer
Alberto Siccardi Executive Chairman
Corrado Farsetta Chief Financial Officer
Maria Luisa Siccardi Tonolli Non-Executive Director
Victor Waldemar Balli Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA17.54%1 882
ALIGN TECHNOLOGY, INC.70.41%37 493
SARTORIUS STEDIM BIOTECH98.78%32 358
SYSMEX CORPORATION40.76%21 519
AMERISOURCEBERGEN CORPORATION21.28%21 079
BIO-RAD LABORATORIES, INC.44.60%15 912